Understanding how obesity-related factors influence prostate cancer progression
Integrating Tissue-based Spatial Information to Elucidate How Obesity-induced Tumour Metabolites Drive Prostate Cancer Progression
This study looks at how being overweight or obese affects prostate cancer by checking certain enzymes and immune cells in tumor samples from patients with different body weights.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06292897 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters in prostate cancer tissues from patients with varying body mass indices (BMI). It aims to characterize the immune cell presence in these tumors and assess how lactate accumulation relates to changes in the tumor immune environment and oncogenic pathways. By comparing severely overweight/obese patients to those with normal weight, the study seeks to uncover metabolic influences on cancer progression.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with prostate cancer, particularly those with a BMI greater than 27.5.
Not a fit: Patients who are not affected by prostate cancer or have a BMI less than or equal to 27.5 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how obesity impacts prostate cancer progression, potentially leading to targeted therapies.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have explored the relationship between obesity and cancer progression, indicating potential for meaningful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * affected by prostate cancer Exclusion Criteria: \-
Where this trial is running
Milan
- IRCCS Cà Granda Ospedale Maggiore Policlinico Milano — Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Giancarlo Albo, MD,
- Email: giancarlo.albo@policlinico.mi.it
- Phone: 00390255034501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.